The Lessons of CATIE
By Jonathan Scheff
The landmark study found that older antipsychotics were just as effective as newer ones. Is anyone listening?

When the results of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) were published in 2005, researchers presented clinicians with a surprise: Doctors had thought that second-generation, or atypical, antipsychotic medications were more effective, and produced fewer extrapyramidal side effects, such as tremors, rigidity, restlessness, and tardive dyskinesia, than their predecessors. However, the National Institute of Mental Health study found no significant difference between the generations in terms of efficacy, and only small differences in terms of side-effect profiles (NEJM, 353:1209-23, 2005).

For example, patients discontinued olanzapine, an atypical antipsychotic, and perphenazine, a typical antipsychotic, at the same rate due to...

Interested in reading more?

Magaizne Cover

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?